A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States by Livorsi, Daniel J. et al.
RESEARCH Open Access
A systematic review of the epidemiology of
carbapenem-resistant Enterobacteriaceae in
the United States
Daniel J. Livorsi1,2*† , Margaret L. Chorazy3†, Marin L. Schweizer1,2, Erin C. Balkenende1, Amy E. Blevins4,5,
Rajeshwari Nair1,2, Matthew H. Samore6,7, Richard E. Nelson6,7, Karim Khader6,7 and Eli N. Perencevich1,2
Abstract
Background: Carbapenem-resistant Enterobacteriaceae (CRE) pose an urgent public health threat in the United
States. An important step in planning and monitoring a national response to CRE is understanding its epidemiology
and associated outcomes. We conducted a systematic literature review of studies that investigated incidence and
outcomes of CRE infection in the US.
Methods: We performed searches in MEDLINE via Ovid, CDSR, DARE, CENTRAL, NHS EED, Scopus, and Web of
Science for articles published from 1/1/2000 to 2/1/2016 about the incidence and outcomes of CRE at US sites.
Results: Five studies evaluated incidence, but many used differing definitions for cases. Across the entire US
population, the reported incidence of CRE was 0.3–2.93 infections per 100,000 person-years. Infection rates were
highest in long-term acute-care (LTAC) hospitals. There was insufficient data to assess trends in infection rates over
time. Four studies evaluated outcomes. Mortality was higher in CRE patients in some but not all studies.
Conclusion: While the incidence of CRE infections in the United States remains low on a national level, the
incidence is highest in LTACs. Studies assessing outcomes in CRE-infected patients are limited in number, small in
size, and have reached conflicting results. Future research should measure a variety of clinical outcomes and
adequately adjust for confounders to better assess the full burden of CRE.
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Background
The Centers for Disease Control and Prevention (CDC)
in the United States has deemed carbapenem-resistant
Enterobacteriaceae (CRE) an urgent public health threat
that requires immediate and aggressive action [1]. The
reason for this urgency is clear: CRE infections are re-
sistant to nearly all antibiotics and are associated with
poor clinical outcomes [2].
Carbapenem-resistance in Enterobacteriaceae can result
from a variety of mechanisms [3]. In the US, CRE isolates
commonly produce carbapenemases; these enzymes are
carried on plasmids and can be easily shared with other
gram-negative bacteria. The Klebsiella pneumoniae carba-
penemase (KPC) was first recognized in North Carolina in
1996 and has since spread around the world [4]. Other
examples of carbapenemases include the New Delhi
Metallo-β-lactamase (NDM), Verona Integron-encoded
Metallo-β-lactamase (VIM), Oxacillinase-48-type carbape-
nemases (OXA-48), and imipenemase (IMP).
CRE infections are typically seen in patients with prior
healthcare exposure, and medical devices are a common
risk factor for CRE acquisition [5]. According to 2009–
2010 data from the National Healthcare Safety Network
(NHSN), 20% of hospitals reporting central line-associated
bloodstream infections (CLABSIs) or catheter-associated
urinary tract infections (CAUTIs) due to Klebsiella spp. re-
ported at least 1 carbapenem-resistant strain [6]. In 2013,
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an outbreak of NDM-producing Escherichia coli was asso-
ciated with duodenoscopes at an Illinois hospital [7].
Despite ongoing control efforts, CRE has become preva-
lent in several US regions, including Orange County, Cali-
fornia and the Chicago metropolitan area [8, 9]. CRE has
been endemic in the New York/New Jersey area since the
early 2000s [10]. According to the 2013 CDC Antibiotic
Resistance Threat Report, there are 9000 healthcare-
associated CRE infections every year in the US, resulting
in 600 deaths (mortality rate 6.6%) [1]. However, such a
low proportion of deaths may be an underestimation due
to how infections were defined.
The CDC has published toolkits on preventing the
spread of CRE within and between healthcare facilities
[3, 11]. While these toolkits have aided efforts at CRE
prevention, a better understanding of the epidemiology
and burden of CRE is critical to encourage increased in-
vestments in the study and prevention of these patho-
gens. To this end, we conducted a systematic review and
evaluation of studies which investigated incidence and
outcomes of CRE infection at US sites.
Methods
Search strategy
This systematic literature review was performed accord-
ing to the MOOSE and PRISMA guidelines [12, 13]. An
experienced health sciences librarian conducted system-
atic searches in MEDLINE via Ovid, Cochrane Database
of Systematic Reviews via Wiley (CDSR), Database of Ab-
stracts of Reviews of Effects via Wiley (DARE), Cochrane
Central Register of Controlled Trials via Wiley (CEN-
TRAL), NHS Economic Evaluation Database (NHS EED)
via Wiley, Scopus, and Web of Science. We searched for
articles published between the dates January 1, 2000 and
February 1, 2016. Search terms included Medical Subject
Headings (MeSH) and keywords for carbapenem resistance,
Enterobacteriaceae, adverse events, incidence, prevalence,
and economics. Additional file 1 includes a description of
the complete search strategy. We reviewed the reference
lists from each article to identify additional studies.
Inclusion and exclusion criteria
Studies were included if they (1) were conducted in the
United States; (2) evaluated incidence of CRE or out-
comes attributed to CRE infections including mortality,
length of stay (LOS), discharge to a long-term acute-care
(LTAC) hospitals, readmission, recurrence, and costs; (3)
included at least 7 study sites (incidence studies only);
and (4) used either the CDC’s original or revised defin-
ition for CRE [3, 11]. In the original definition, an
Enterobacteriaceae isolate qualified as CRE if it was
non-susceptible to imipenem, meropenem or doripenem
AND resistant to all of the following third-generation
cephalosporins: ceftriaxone, cefotaxime and ceftazidime
[11]. In the revised 2015 definition, an Enterobacteria-
ceae isolate qualified as CRE if it was resistant to imipe-
nem, meropenem, or doripenem, (minimum inhibitory
concentration [MIC] ≥ 4 mcg/mL) OR resistant to ertape-
nem (MIC ≥2 mcg/mL) OR had documented production
of a carbapenemase [3]. In 2010, the Clinical and Labora-
tory Standards Institute (CLSI) lowered the breakpoints
for carbapenems by a factor of 4, so in reviewing each
study, we made note of which version of the CLSI break-
points was used.
We excluded studies that (1) were less than 6 months
in duration; (2) used International Classification of Dis-
eases Clinical Modification diagnosis codes to define
CRE infections; (3) used surveillance cultures from non-
sterile body sites to detect CRE; (4) did not have a de-
nominator or control group; (5) took place during an
outbreak; (6) were mathematical models; (7) did not
contain original data; and (8) were published in a lan-
guage other than English. We excluded studies evaluat-
ing LOS or costs if they did not measure post-infection
LOS or costs, or if they did not match infected cases
and uninfected controls on time at risk (time from ad-
mission to infection for cases, time from admission to
discharge for uninfected controls) or did not match on
propensity scores.
Data extraction and quality assessment
One investigator (MLC) reviewed the titles and abstracts
of all articles for inclusion and exclusion criteria. Two of
four reviewers (MLC, RN, ENP, MLS) independently ab-
stracted data for each included study. Disagreements be-
tween reviewers were resolved by consensus.
The reviewers abstracted data on the following items:
study design, population and setting, location, definition
of CRE infection, incidence data, prevalence data, mor-
tality, LOS, discharge to LTAC, readmission, recurrence,
and cost. Additional data were collected regarding tests
used to identify CRE infection, identification of different
species that were identified as CRE, and definitions of
resistance.
Risk of bias was assessed using the Newcastle-Ottawa
scale for included studies [14].
Results
We screened 18,178 unique studies for eligibility (Fig. 1).
Nine studies were eligible for inclusion, including 5 mul-
ticenter studies reporting the incidence of CRE infec-
tions [15–19] and 4 studies (2 multicenter and 2 single
center) evaluating relevant outcomes [20–23]. Included
studies were of moderate-to-high risk of bias according
to the Newcastle-Ottawa tool (Table 1). Included studies
had low risk of bias when it came to representativeness
and ascertainment of CRE infected patients and controls.
However, most of the included studies had high risk of
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bias in terms of adequacy of follow-up, cohort design
and analysis, and assessment of outcomes.
Incidence of CRE infections
There were 5 studies (Table 2) that measured the in-
cidence of CRE: 4 studies used the lower CLSI break-
points (i.e. 2010 and later) [15–18] while one study
largely used the pre-2010 breakpoints [19]. All studies
included clinical cultures from sterile and non-sterile
body sites, but one study limited non-sterile cultures
to only urine samples [18].
Three studies used the denominator of patient-days
[15, 17, 19], but these 3 studies could not be pooled be-
cause definitions varied: 1 study included all species of
Enterobacteriaceae while 2 studies used less inclusive
definitions. Among these 3 studies, the incidence of CRE
ranged from 0.46 CRE infections per 10,000 patient-days
to 4.17 CRE infections per 10,000 patient-days. Two
studies stratified by long-term acute care (LTAC) hospi-
tals and acute care hospitals [15, 17]. One of these
studies–which took place in Los Angeles County, Cali-
fornia—found that the incidence of CRE infections in
acute care hospitals was 0.31 per 10,000 patients-days
and the incidence of CRE infections in LTAC hospitals
was 2.54 per 10,000 patient-days [17]. The other study,
which took place in Michigan, found a similar inci-
dence of CRE infections in LTAC hospitals (2.93 per
10,000 patient-days) but the incidence of CRE infec-
tions among the acute care hospitals (1.01 per 10,000
patient-days) was higher than that of the Los Angeles
County study [15].
Two studies included both inpatients and outpatients,
reflected in a denominator of person-years [16, 18]. In a
study of the civilian component of the US military health
care system, the incidence of CRE remained steady at 0.
49 infections per 100,000 person-years between 2005
Fig. 1 Flow diagram of search strategy. Legend: CRE, Carbapenem-resistant Enterobacteriaceae; LOS, length of stay; LTAC, long-term
acute-care hospital
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and 2012; the peak incidence was 0.67 per 100,000 per-
son years in the year 2010 [16]. A study across 7 metro-
politan areas estimated an incidence of 2.94 cases per
100,000 persons in 2012 and 2.93 per 100,000 persons in
2013. Site-specific incidence rates ranged from 0.82
cases per 100,000 persons in Oregon to 4.80 cases per
100,000 persons in Maryland [18].
Carbapenemase production was assessed in 2 studies
[15, 18]. One study only included isolates with a positive
or unknown result on the Modified-Hodge Test (MHT),
but a breakdown of MHT results was not provided [15].
In another study, 90 of 188 (47.9%) isolates across 6 sites
produced a carbapenemase, all of which were KPCs [18].
Outcomes attributable to CRE infections
Each of the 5 outcomes studies included data from 2009
or earlier (Table 3). Two studies evaluated outcomes in
CRE patients compared to uninfected controls [20, 23].
In the earliest study, all patients who underwent liver
transplantation at a single center were followed for 1 year
after transplantation [23]. That study found that 71% of
the patients infected with carbapenem-resistant K.
pneumoniae (CRKP) died compared to 14% of the unin-
fected patients (log rank p < 0.001). Based on a multi-
variate Cox proportional hazards analysis, mortality at 1-
year was significantly higher in patients who developed
CRKP infections compared to uninfected patients (haz-
ard ratio = 4.9, 95% CI 1.5–15.6). In the second study,
patients with and without infections were matched by
hospital or facility, unit or clinic, calendar year, and time
at risk (i.e., from admission to culture). This study found
higher odds of dying among CRE patients compared
with uninfected controls, but the difference was not sta-
tistically significant (OR = 1.6; 95% CI: 0.7–3.3) [20]. The
study also found that CRE infected patients had signifi-
cantly higher odds of being discharged to a LTAC after
being admitted from home (OR = 13.7; 95% CI: 4.3–44.
4). There was no difference in LOS between CRE and
uninfected patients.
Three studies evaluated outcomes in patients with
CRE compared to carbapenem-susceptible Enterobac-
teriaceae (CSE) [20–22]. Two studies only included
isolates of K. pneumoniae while the third study
included all types of CSE not producing extended-
Table 1 Risk of bias assessment of CRE studies using Newcastle Ottawa tool (Stang 2010). Receiving a star (*) represents that the
study has low risk of bias and high quality in that category
Selection Comparability Outcome
Author
(Year)
Representative-ness
of the exposed
cohort
Selection of the
non-exposed
cohort
Ascertainment
of exposure
Demonstration that
outcome of interest
was not present at
start of study
Comparability of
cohorts on the
basis of design
or analysis
Assessment
of outcome
Was follow-up
long enough
for outcomes to
occur
Adequacy
of follow-up
of cohorts
Bogan
(2014)
[20]
* * * * * * * _
Brennan
(2014)
[15]
* * * * _ _ _ _
Gasink
(2009)
[21]
* * * * * * * _
Guh
(2015)
[18]
* * * * _ _ _ _
Lesho
(2015)
[16]
* * * * _ _ _ _
Marquez
(2013)
[17]
* * * _ _ _ _ _
Patel
(2008)
[22]
* * * * * * * _
Thaden
(2014)
[19]
* * * * _ _ _ _
Kalpoe
(2012)
[23]
* * * * * * * *
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spectrum beta-lactamases (ESBLs). Two studies used
multivariable analysis to adjust for important predic-
tors of mortality; only one of these studies adjusted
for severity of illness [21] while the other matched
cases-and-controls on baseline factors [20]. The third
study matched patients with CRE to those with CSE
based on body-site of infection [22].
In both studies that exclusively evaluated K. pneumo-
niae, cases with carbapenem-resistance had significantly
higher odds of all-cause in-hospital mortality (OR = 2.28
and OR = 3.71; Table 3) [21, 22]. One of these studies
also found that the odds of attributable in-hospital
mortality were more than 4-fold higher among CRKP-
infected patients compared with carbapenem-susceptible
K. pneumoniae infected controls [22]. In the study that in-
cluded all types of Enterobacteriaceae, carbapenem-
resistance was not significantly associated with either an
increase in hospital mortality (adjusted OR 2.7, 95%
CI 0.8–9.4) or a longer LOS. However, carbapenem-
resistance was associated with being discharged to a
LTAC after being admitted from home (OR = 14.5,
95% CI 2.7–79.8).
Discussion
Estimating the incidence of CRE is an important step in
designing a national public health response to this emer-
ging pathogen [24]. Our review found that the reported
incidence of CRE in the US was 0.3–2.93 infections per
100,000 person-years. The incidence of CRE is relatively
higher in LTACs compared to acute-care hospitals and
community settings. In 1 population-based study, nearly
half of CRE isolates produced a carbapenemase.
Carbapenemase-producing CRE are of the greatest epi-
demiologic concern, because these enzymes are typically
carried on mobile genetic elements that can be shared
with other bacteria [25].
Based on our findings, CRE is still relatively uncom-
mon in the US compared to other antibiotic-resistant
pathogens. For example, the estimated incidence of inva-
sive methicillin-resistant Staphylococcus aureus (MRSA)
Table 2 Studies that Evaluated CRE Incidence
First Author
(Year)
Study Population CLSI protocol Study Period Culture type # of
Infections
IncidenceRate
Brennan (2014)
[15]
CRE Surveillance and
Prevention Initiative
in Michigan
M100-S22 2012 09/2012–02/2013 All cultures positive for carbapenem
non-susceptible K. pneumoniae or
E.coli. All cases had a positive or
unknown modified Hodge-Test
result. Only 1 case per patient
per 30-day period.
102 Per 10,000
patient-days
Overall: 1.07
Acute care: 1.01
LTAC: 2.93
East: 1.24
West: 0.52
Mid-North: 0.36
Lesho (2015)
[16]
Tricare, i.e.civilian
component of the
US military health
care system
M100-S20–2010 01/2005–12/2012 All CRE-positive cultures
(E.coli, Klebsiella spp., Enterobacter spp.).
For each year of surveillance, the first
CRE-positive culture per patient was
included.
368 Per 100,000
person-years
All Years: 0.487
2012: 0.394
2011: 0.528
2010: 0.672
2009: 0.607
2008: 0.439
2007: 0.424
2006: 0.490
2005: 0.335
Marquez
(2013) [17]
Los Angeles County M100-S20 2010 06/2010–05/2011 All cultures positive for
carbapenem-resistant K. pneumoniae.
Only 1 isolate allowed per patient
per calendar month.
675 Per 1000
patient-days
Acute and
LTAC: 0.46
LTAC only: 2.54
Acute only: 0.31
Thaden (2014)
[19]
Duke Infection
Control Outreach
Network (DICON)
M100-S20 2010
(20%) sites; earlier
CLSI definitions
(80% sites)
01/2008–12/2012 All CRE-positive cultures. Only 1
culture was allowed per patient
for the entire surveillance period.
180 Per 100,000
patient-days
2008: 0.26
2012: 1.4
Guh (2015)
[18]
Multi-site Gram-negative
Surveillance Initiative
M100-S22 2012 1/2012–12/2013 All CRE non-susceptible cultures
(E.coli, Klebsiella spp., Enterobacter spp.)
from a normally sterile site or urine.
An incident case was defined as the
first isolate from a patient per 30-day
period.
599 Per 100,000
persons
2012: 2.94
2013: 2.93
CLSI Clinical and Laboratory Standards Institute, CRE carbapenem-resistant Enterobacteriaceae, LTAC long-term acute-care hospital
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infections in 2011 across the US was 25 per 100,000 per-
sons, or at least 8 times more common than CRE [26].
In the Veterans Health Administration during 2009–
2013, the overall incidence of C. difficile was approxi-
mately 200 infections per 100,000 patient-years, which
was at least 65 times more common than CRE [27]. It is
important to note that, even though the current inci-
dence of CRE is low, CRE has been rapidly spreading
across the US. Prior to 1996, carbapenemase-producing
CRE was not reported in the US, but as of August 2017,
this pathogen has been reported in every US state but
Idaho [28].
Despite its low incidence, CRE remains a public health
threat due to its limited treatment options and worse clin-
ical outcomes [1]. Based on the studies that compared
outcomes between CRE and uninfected patients, infection
with CRE was associated with a higher risk of being dis-
charged to a LTAC and a higher risk of death within the
year after liver transplantation [20, 23]. Studies consist-
ently reported an unadjusted CRE-related mortality rate
that was higher than the 6.6% estimate from the CDC [1].
Surprisingly, however, patients with CRE were not al-
ways found to have an increased risk for death compared
with controls. Studies that compared CRE to uninfected
patients reached different conclusions on mortality, al-
beit using different definitions of mortality [20, 23]. Con-
flicting results on mortality were also seen in studies that
compared CRE to CSE. Two studies found that patients
with carbapenem-resistant K. pneumoniae had 2–3 times
the odds of in-hospital death as patients with
carbapenem-susceptible K. pneumoniae, but a similar dif-
ference in mortality was not seen in a study that included
all types of Enterobacteriaceae (i.e., CRE compared with
CSE). In contrast, evidence from outside the United States
shows increased mortality with CRE. A case-control study
from Israel found that, after adjusting for severity of ill-
ness, patients with infections from carbapenem-resistant
K. pneumoniae had 4 times the risk of death as patients
infected with carbapenem-susceptible K. pneumoniae [29].
While it seems intuitive that CRE would be associated
with worse outcomes, the lack of consistency across the
literature raises several important questions about how
CRE cases are defined and how CRE outcomes are mea-
sured. First, only 2 studies in this systematic literature
review restricted cases to patients with CRE-positive cul-
tures from normally sterile body sites. As a result, there
is potential that patients colonized with CRE (i.e., a posi-
tive culture from a non-sterile site in the absence of
signs or symptoms of infection) were included as “in-
fected” cases. Such a misclassification bias could obscure
differences in outcomes. As with any bacteria, the body
site of infection is a key determinant of outcomes. A
CRE bacteremia, for example, would be expected to have
a higher mortality rate than a CRE urinary tract
infection. In fact, a case-control study from Israel found
that carbapenem-resistant K. pneumoniae bacteremia
has an attributable mortality of 50%, or 3 times the risk
of death compared with non-bacteremic controls [30].
Second, patients with CRE may have a higher risk of
death for reasons beyond the infection itself. For ex-
ample, CRE-positive patients may have a higher burden
of comorbidities and, due to these comorbidities, be
more acutely ill when they do become infected. These
factors were not adequately accounted for in all studies.
Third, it is possible that outcomes other than mortality
are worse in patients with CRE, but these alternate out-
comes have gone unmeasured. For example, none of the
studies measured hospital re-admissions and costs.
Another potential explanation for the conflicting mor-
tality results is that the current studies were underpow-
ered to find statistically significant results. Each of the 4
studies that evaluated mortality included fewer than 100
CRE-infected patients. In the future, larger well-designed
studies should be performed to assess the association be-
tween CRE infection and mortality.
All the studies included in this systematic literature re-
view evaluated outcomes before the Food and Drug Ad-
ministration’s (FDA) approval of ceftazidime-avibactam
and meropenem-vaborbactam. Now that these new and
potentially more efficacious agents are available, a re-
evaluation of CRE-related outcomes is warranted.
There are several limitations to our meta-analysis.
First, definitions of CRE varied across studies. This dis-
crepancy reflects differences in how each study chose to
define a CRE case; it also reflects changes in the CDC’s
definition for CRE and the CLSI’s breakpoints for
carbapenem-resistance. The original CDC definition for
CRE did not include ertapenem, which limited its sensi-
tivity for detecting OXA-48-producing CRE. Further-
more, studies that used the pre-2010 CLSI guidelines to
define carbapenem-resistance or evaluated just certain
species of Enterobacteriaceae may have under-
estimated the true incidence of CRE [19, 31]. Thus,
we were unable to pool data using meta-analytic
techniques. Second, while we excluded studies that
used surveillance cultures, clinical cultures reflecting
colonization of a non-sterile site were not consistently
distinguished from true infections. This may have re-
sulted in an overestimation of the incidence of infec-
tion and an underestimation of the risk of mortality.
Third, our incidence rates were derived from a lim-
ited number of geographic regions and not the entire
US. However, 2 studies included multiple states,
which should increase the generalizability of our find-
ings. Fourth, outcome studies were limited in both
number and quality. For example, 3 of the 4 studies
involved ≤2 hospitals, and only 1 adjusted for severity
of illness, a key determinant of mortality.
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Conclusions
In conclusion, while the incidence of CRE infections in
the United States remains low on a national level, the in-
cidence is highest in LTACs. Several studies have mea-
sured the incidence of CRE, but the percentage of CRE
that results from carbapenemase-production needs to be
better defined. Studies assessing outcomes in CRE-
infected patients have been small and have reached con-
flicting results. Future research should measure a variety
of clinical outcomes, should be adequately powered and
should adequately adjust for confounders to better assess
the full burden of CRE. Specifically, outcomes of CRE
infections treated with recently FDA-approved antibi-
otics warrant further evaluation.
Without adequate studies measuring the burden of
CRE infections, proper distribution of resources for
research and prevention efforts will be impossible,
thereby leaving patients vulnerable to this important
emerging pathogen.
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